Enhanced expression of myogenic differentiation factors and skeletal muscle proteins in human amnion-derived cells via the forced expression of MYOD1

Brain and Development

Volumn 35, Issue 4, 2013, Pages 349-355

  Akizawa, Yoshika ^a   Kanno, Hitoshi ^a   Kawamichi, Yayoi ^a   Matsuda, Yoshio ^a   Ohta, Hiroaki ^b   Fujii, Hisaichi ^a   Matsui, Hideo ^a   Saito, Kayoko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Cellular therapy; Duchenne muscular dystrophy; Dystrophin; Gene therapy; Mesenchymal stem cell; Placenta

Indexed keywords

DMD PROTEIN; LENTIVIRUS VECTOR; MEMBRANE PROTEIN; MESSENGER RNA; MUSCLE PROTEIN; MYH 2 PROTEIN; MYOD1 PROTEIN; MYOG PROTEIN; MYOGENIC FACTOR; MYOGENIC FACTOR 5; SKELETAL MUSCLE PROTEIN; UNCLASSIFIED DRUG;

AMNION CELL; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PLACENTA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AMNION; ANTIGENS, CD; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LENTIVIRUS; MUSCLE DEVELOPMENT; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOD PROTEIN; PREGNANCY; RNA, MESSENGER; STEM CELLS; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 84875514974     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2012.05.012     Document Type: Article

References (31)

1. Nowak K., Davies K.E. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 2004, 5:872-876.
2. Ahn A.H., Kunkel L.M. The structural and functional diversity of dystrophin. Nat Genet 1993, 3:283-291.
3. Wang B., Li J., Qiao C., Chen C., Hu P., Zhu X., et al. A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther 2008, 15:1099-1106.
4. Matsuo M., Masumura T., Nishio H., Nakajima T., Kitoh Y., Takumi T., et al. Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe. J Clin Invest 1991, 87:2127-2131.
5. Barton-Davis E.R., Cordier L., Shoturma D.I., Leland S.E., Sweeney H.L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999, 104:375-381.
6. Kebriaei P., Isola L., Bahceci E., Holland K., Rowley S., McGuirk J., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
7. Ko I.K., Kim B.G., Awadallah A., Mikulan J., Lin P., Letterio J.J., et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther 2010, 18:1365-1372.
8. Portmann-Lanz C.B., Schoeberlein A., Huber A., Sager R., Malek A., Holzgreve W., et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006, 194:664-673.
9. Drost A.C., Weng S., Feil G., Schäfer J., Baumann S., Kanz L., et al. In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann NY Acad Sci 2009, 1176:135-143.
10. Lattanzi L., Salvatori G., Coletta M., Sonnino C., Cusella De Angelis M.G., Gioglio L., et al. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest 1998, 101:2119-2128.
11. Goudenege S., Pisani D.F., Wdziekonski B., Di Santo J.P., Bagnis C., Dani C., et al. Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD. Mol Ther 2009, 17:1064-1072.
12. Cooper S.T., Kizana E., Yates J.D., Lo H.P., Yang N., Wu Z.H., et al. Dystrophinopathy carrier determination and detection of protein deficiencies in muscular dystrophy using lentiviral MyoD-forced myogenesis. Neuromuscul Disord 2007, 17:276-284.
13. Itoh M., Yasunishi A., Imamura K., Kanamori-Katayama M., Suzuki H., Suzuki M., et al. Constructing ORFeome resources with removable termination codons. Biotechniques 2006, 41:44,46,48.
14. Kimura K., Wakamatsu A., Suzuki Y., Ota T., Nishikawa T., Yamashita R., et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res 2006, 16:55-65.
15. Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 2004, 36:40-45.
16. Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., et al. Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries. DNA Res 2005, 12:117-126.
17. Godmann M., May E., Kimmins S. Epigenetic mechanisms regulate stem cell expressed genes Pou5f1 and Gfra1 in a male germ cell line. PLoS One 2010, 5:e12727.
18. Nabeshima Y., Hanaoka K., Hayasaka M., Esumi E., Li S., Nonaka I. Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 1993, 364:532-535.
19. Rudnicki M.A., Schnegelsberg P.N., Stead R.H., Braun T., Arnold H.H., Jaenisch R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 1993, 75:1351-1359.
20. Parker M.H., Seale P., Rudnicki M.A. Looking back to the embryo: defining transcriptional networks in adult myogenesis. Nat Rev Genet 2003, 4:497-507.
21. Rudnicki M.A., Le Grand F., McKinnell I., Kuang S. The molecular regulation of muscle stem cell function. Cold Spring Harb Symp Quant Biol 2008, 73:323-331.
22. Chargé S.B., Rudnicki M.A. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004, 84:209-238.
23. Kawamichi Y., Cui C.H., Toyoda M., Makino H., Horie A., Takahashi Y., et al. Cells of extraembryonic mesodermal origin confer human dystrophin in the mdx model of Duchenne muscular dystrophy. J Cell Physiol 2010, 223:695-702.
24. González-Ramírez R., Morales-Lázaro S.L., Tapia-Ramírez V., Mornet D., Cisneros B. Nuclear and nuclear envelope localization of dystrophin Dp71 and dystrophin-associated proteins (DAPs) in the C2C12 muscle cells: DAPs nuclear localization is modulated during myogenesis. J Cell Biochem 2008, 105:735-745.
25. Bujang-Safawi E., Halim A.S., Khoo T.L., Dorai A.A. Dried irradiated human amniotic membrane as a biological dressing for facial burns - a 7-year case series. Burns 2010, 36:876-882.
26. Kolli S., Ahmad S., Lako M., Figueiredo F. Successful clinical implementation of corneal epithelial stem cell therapy for treatment of unilateral limbal stem cell deficiency. Stem Cells 2010, 28:597-610.
27. Mermet I., Pottier N., Sainthillier J.M., Malugani C., Cairey-Remonnay S., Maddens S., et al. Use of amniotic membrane transplantation in the treatment of venous leg ulcers. Wound Repair Regen 2007, 15:459-464.
28. Cargnoni A., Gibelli L., Tosini A., Signoroni P.B., Nassuato C., Arienti D., et al. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant 2009, 18:405-422.
29. Chen Z., Tortella F.C., Dave J.R., Marshall V.S., Clarke D.L., Sing G., et al. Human amnion-derived multipotent progenitor cell treatment alleviates traumatic brain injury-induced axonal degeneration. J Neurotrauma 2009, 26:1987-1997.
30. Dekaris I., Gabrić N. Preparation and preservation of amniotic membrane. Dev Ophthalmol 2009, 43:97-104.
31. Toda A., Okabe M., Yoshida T., Nikaido T. The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. J Pharmacol Sci 2007, 105:215-228.